Cinctive Capital Management LP Takes Position in Repligen Corporation $RGEN

Cinctive Capital Management LP bought a new stake in shares of Repligen Corporation (NASDAQ:RGEN) during the 3rd quarter, according to its most recent filing with the SEC. The firm bought 25,420 shares of the biotechnology company’s stock, valued at approximately $3,398,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Alliancebernstein L.P. grew its position in Repligen by 21.8% in the third quarter. Alliancebernstein L.P. now owns 1,104,171 shares of the biotechnology company’s stock valued at $147,595,000 after acquiring an additional 197,778 shares in the last quarter. Brown Capital Management LLC lifted its position in shares of Repligen by 16.3% during the second quarter. Brown Capital Management LLC now owns 1,005,276 shares of the biotechnology company’s stock worth $125,036,000 after purchasing an additional 141,241 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of Repligen by 4.1% in the third quarter. Dimensional Fund Advisors LP now owns 799,510 shares of the biotechnology company’s stock valued at $106,826,000 after purchasing an additional 31,505 shares during the period. Balyasny Asset Management L.P. boosted its stake in shares of Repligen by 390.6% in the third quarter. Balyasny Asset Management L.P. now owns 767,239 shares of the biotechnology company’s stock valued at $102,557,000 after purchasing an additional 610,837 shares during the period. Finally, Stephens Investment Management Group LLC grew its holdings in Repligen by 14.4% during the 3rd quarter. Stephens Investment Management Group LLC now owns 598,356 shares of the biotechnology company’s stock valued at $79,982,000 after purchasing an additional 75,509 shares in the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Repligen Stock Performance

Shares of RGEN opened at $114.20 on Monday. The business’s fifty day moving average price is $145.43 and its 200 day moving average price is $147.05. Repligen Corporation has a 12-month low of $102.96 and a 12-month high of $175.77. The stock has a market capitalization of $6.43 billion, a PE ratio of 134.35, a price-to-earnings-growth ratio of 2.23 and a beta of 1.15. The company has a debt-to-equity ratio of 0.26, a current ratio of 8.37 and a quick ratio of 7.12.

Repligen (NASDAQ:RGEN) last released its earnings results on Tuesday, February 24th. The biotechnology company reported $0.49 earnings per share for the quarter, beating the consensus estimate of $0.44 by $0.05. The firm had revenue of $197.91 million during the quarter, compared to analyst estimates of $192.23 million. Repligen had a net margin of 6.62% and a return on equity of 4.71%. The firm’s revenue for the quarter was up 18.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.44 earnings per share. Repligen has set its FY 2026 guidance at 1.930-2.010 EPS. Equities research analysts forecast that Repligen Corporation will post 1.72 EPS for the current year.

Insider Activity at Repligen

In related news, Director Karen A. Dawes sold 275 shares of the business’s stock in a transaction dated Wednesday, December 17th. The shares were sold at an average price of $161.00, for a total transaction of $44,275.00. Following the completion of the sale, the director owned 91,821 shares of the company’s stock, valued at $14,783,181. This represents a 0.30% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 1.20% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on RGEN shares. KeyCorp reaffirmed an “overweight” rating on shares of Repligen in a research note on Wednesday, February 25th. Wall Street Zen cut shares of Repligen from a “buy” rating to a “hold” rating in a research report on Saturday, February 28th. Barclays dropped their target price on Repligen from $200.00 to $175.00 and set an “overweight” rating on the stock in a research report on Wednesday, February 25th. Wells Fargo & Company cut their price target on Repligen from $190.00 to $180.00 and set an “overweight” rating on the stock in a research note on Wednesday, February 25th. Finally, Weiss Ratings downgraded Repligen from a “hold (c-)” rating to a “sell (d+)” rating in a report on Tuesday, March 3rd. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $174.58.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.